It was an exciting day for Bristol-Myers Squibb on Monday. The Food and Drug Administration has approved the company’s immuno-oncology drug Opdivo for intravenous use for patients with hepatocellular carcinoma (HCC) who have been previously treated with Nexavar. Hepatocellular carcinoma is the most common type of liver cancer there is. The approval of the drug … Continue reading “Bristol-Myers Squibb Gets FDA Approval for its Liver Drug Opdivo”
September 25, 2017
Biotech & Pharma